Clear All
11465 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
83634-0779-02 83634-0779 Metoclopramide hydrochloride Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Jun 30, 2024 In Use
83634-0801-05 83634-0801 Zoledronic acid Zoledronic Acid 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous Jan 15, 2025 In Use
83703-0531-02 83703-0531 Palonosetron hydrochloride Palonosetron Hydrochloride 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Nov 12, 2021 In Use
83703-0532-01 83703-0532 Bortezomib BORTEZOMIB 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use
83703-0533-01 83703-0533 Bendamustine hydrochloride BENDAMUSTINE HYDROCHLORIDE 100.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Dec 15, 2022 In Use
83703-0561-01 83703-0561 PEMETREXED PEMETREXED 100.0 mg/10mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Aug 18, 2022 In Use
83703-0562-01 83703-0562 PEMETREXED PEMETREXED 500.0 mg/50mL Chemotherapy Antimetabolite Folic Acid Analog INTRAVENTRICULAR Aug 18, 2022 In Use
83718-0000-01 83718-0000 Toripalimab-tpzi LOQTORZI 240.0 mg/6mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Oct 27, 2023 In Use
83774-0100-60 83774-0100 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Feb 27, 2024 In Use
83774-0101-12 83774-0101 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Feb 27, 2024 In Use
83774-0102-01 83774-0102 Azacitidine AZACITIDINE 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Mar 14, 2024 In Use
83831-0101-02 83831-0101 Docetaxel DOCIVYX 20.0 mg/2mL Chemotherapy Antimitotic Agent Taxane Intravenous May 9, 2024 In Use
83831-0102-08 83831-0102 Docetaxel DOCIVYX 80.0 mg/8mL Chemotherapy Antimitotic Agent Taxane Intravenous May 9, 2024 In Use
83831-0103-16 83831-0103 Docetaxel DOCIVYX 160.0 mg/16mL Chemotherapy Antimitotic Agent Taxane Intravenous May 9, 2024 In Use
83831-0104-05 83831-0104 Palonosetron Posfrea 0.075 mg/1.5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Sep 30, 2024 Sep 30, 2024 No Longer Used
83831-0105-01 83831-0105 Palonosetron Posfrea 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Sep 30, 2024 In Use
83831-0111-01 83831-0111 Pemetrexed dipotassium PEMETREXED DIPOTASSIUM 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Jan 1, 2025 In Use
83831-0112-01 83831-0112 Pemetrexed dipotassium PEMETREXED DIPOTASSIUM 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Jan 1, 2025 In Use
83831-0116-01 83831-0116 Cyclophosphamide Cyclophosphamide 500.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Aug 1, 2024 In Use
83831-0117-02 83831-0117 Cyclophosphamide Cyclophosphamide 1.0 g/2mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Aug 1, 2024 In Use
83831-0118-04 83831-0118 Cyclophosphamide Cyclophosphamide 2.0 g/4mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Aug 1, 2024 In Use
83831-0119-01 83831-0119 Cyclophosphamide Frindovyx 500.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Mar 19, 2025 In Use
83831-0120-02 83831-0120 Cyclophosphamide Frindovyx 1.0 g/2mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Mar 19, 2025 In Use
83831-0121-04 83831-0121 Cyclophosphamide Frindovyx 2.0 g/4mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Mar 19, 2025 In Use
83831-0131-01 83831-0131 Pemetrexed AXTLE 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Jan 1, 2025 In Use

Found 11465 results — Export these results